Travere Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Travere Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
TVTX | Travere Therapeutics | -$0.46 | -$0.17 | — | — | $62.90M | $105.01M | — | — | 10/30/2025 | |
TVTX | Travere Therapeutics | -$0.65 | -$0.12 | $0.13 | 146.43% | $52.18M | $99.08M | $114.40M | 15.46% | 08/06/2025 | |
TVTX | Travere Therapeutics | -$1.51 | -$0.39 | -$0.19 | 51.28% | $41.37M | $76.86M | $81.73M | 6.34% | 05/01/2025 | |
TVTX | Travere Therapeutics | -$0.94 | -$0.38 | -$0.47 | -23.68% | $45.06M | $72.38M | $74.79M | 3.33% | 02/20/2025 | |
TVTX | Travere Therapeutics | $2.27 | -$0.68 | -$0.46 | 32.35% | $37.09M | $60.48M | $62.90M | 4.00% | 10/31/2024 | |
TVTX | Travere Therapeutics | -$0.79 | -$0.86 | -$0.65 | 24.42% | $59.70M | $50.17M | $52.18M | 4.00% | 08/01/2024 | |
TVTX | Travere Therapeutics | -$0.92 | -$0.99 | -$1.51 | -52.53% | $30.89M | $42.85M | $41.37M | -3.44% | 05/06/2024 | |
TVTX | Travere Therapeutics | -$0.76 | -$1.26 | -$0.94 | 25.40% | $55.87M | $41.51M | $45.06M | 8.55% | 02/15/2024 | |
TVTX | Travere Therapeutics | -$0.86 | — | $2.27 | — | $28.07M | — | $37.09M | — | 11/07/2023 | |
TVTX | Travere Therapeutics | -$0.65 | -$1.16 | -$0.77 | 33.62% | $54.17M | $53.93M | $59.70M | 10.69% | 08/03/2023 | |
TVTX | Travere Therapeutics | -$0.82 | -$1.17 | -$0.82 | 29.91% | $48.49M | $50.61M | $56.99M | 12.61% | 05/04/2023 | |
TVTX | Travere Therapeutics | -$0.61 | -$1.07 | -$0.76 | 28.97% | $57.25M | $53.01M | $55.87M | 5.39% | 02/23/2023 | |
TVTX | Travere Therapeutics | -$0.13 | -$0.89 | -$0.76 | 14.61% | $68.22M | $54.76M | $53.50M | -2.31% | 10/27/2022 | |
TVTX | Travere Therapeutics | -$0.39 | -$0.88 | -$0.65 | 26.14% | $54.62M | $49.63M | $54.17M | 9.14% | 08/04/2022 | |
TVTX | Travere Therapeutics | -$0.55 | -$0.85 | -$0.82 | 3.53% | $47.41M | $51.92M | $48.49M | -6.61% | 05/05/2022 | |
TVTX | Travere Therapeutics | -$0.48 | -$0.72 | -$0.61 | 15.28% | $50.98M | $57.81M | $57.25M | -0.97% | 02/24/2022 | |
TVTX | Travere Therapeutics | -$0.11 | -$0.54 | -$0.13 | 75.93% | $51.14M | $60.93M | $68.22M | 11.96% | 10/28/2021 | |
TVTX | Travere Therapeutics | -$0.22 | -$0.68 | -$0.39 | 42.65% | $48.43M | $50.33M | $54.62M | 8.52% | 07/29/2021 | |
TVTX | Travere Therapeutics | -$0.20 | -$0.39 | -$0.55 | -41.03% | $47.77M | $50.09M | $47.41M | -5.36% | 05/06/2021 | |
TVTX | Travere Therapeutics | -$0.70 | -$0.47 | -$0.48 | -2.13% | $46.69M | $51.66M | $50.98M | -1.31% | 03/01/2021 | |
TVTX | Travere Therapeutics | -$0.66 | -$0.51 | -$0.11 | 78.43% | $44.37M | $48.14M | $51.14M | 6.23% | 11/05/2020 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-06 | $0.13 | $-0.12 | 146.4 % |
| Q1 | 2025-05-01 | $-0.19 | $-0.39 | 51.3 % |
| Q4 | 2025-02-20 | $-0.47 | $-0.38 | -23.7 % |
| Q3 | 2024-10-31 | $-0.46 | $-0.68 | 32.4 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-06 | $114.40M | $99.08M | 15.5 % |
| Q1 | 2025-05-01 | $81.73M | $76.86M | 6.34 % |
| Q4 | 2025-02-20 | $74.79M | $72.38M | 3.33 % |
| Q3 | 2024-10-31 | $62.90M | $60.48M | 4.00 % |
Si prevede che Travere Therapeutics (TVTX) fornisca risultati il ottobre 30, 2025. Gli ultimi risultati sono stati pubblicati il agosto 6, 2025 per il Q2.
L'EPS effettivo era $0.13, che superato la stima di $-0.12.
Le entrate effettive sono state $114.4M, che superato la stima di $99.1M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.